CLNN Clene Inc

Clene to Present at the 37TH Annual Roth Conference

Clene to Present at the 37TH Annual Roth Conference

SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings.

Date: March 18, 2025

Time of Presentation: 9:20 am PST

Format: Virtual Fireside Chat

1x1 Meetings: Please contact your Roth representative.

A webcast of the presentation will be available on the “” section of the Clene website. Alternatively, one can register online to view the webcast here: .

About Clene

Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit  or follow us on  and .

Contacts:

Media Contact

Ignacio Guerrero-Ros, Ph.D., or David Schull

Russo Partners, LLC





(858) 717-2310		 Investor Contact

Kevin Gardner

LifeSci Advisors



617-283-2856


EN
06/03/2025

Underlying

CLNNClene Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clene Inc

 PRESS RELEASE
Free
CLNN CLENE INC

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Tre...

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Plat...

March 12, 2025 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at the 37TH Annual Roth Conference

Clene to Present at the 37TH Annual Roth Conference SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings. Date: March 18, 2025Time of Presentatio...

March 6, 2025 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene and APST Enter Into an Agreement to Support FDA’s Recommendation...

Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA’s request for supportive evidence of CNM-Au8’s effect on N...

February 25, 2025 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Improves Cash Position and Runway by Securing New Debt Facility ...

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan Secures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt Improves cash position enabling Clene to generate the additional data to support the new drug application of CNM-Au8® for ALS via an accelerated regulatory pathwayCarries a 12% interest rate per annum and is secured by all assets of CleneIncludes conversion feature on 65% of the new debt facility at a fixed conversion price of $5.67, a 130% premium to Clene’s closing stock price on the day of ...

December 19, 2024 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

FDA Provides Roadmap for Accelerated Approval Pathway Through Submissi...

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented findingsFDA recommends a follow-up meeting to discuss in more detail the analyses needed to support the accelerated approval pathway Additional NfL biomarker collection and analyses are underway and planned to be completed during the second quarter of 2025Clene is proceeding with its New Dr...

December 10, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch